

Recommendations for the improvement of bladder cancer
consensus document reviewed and endorsed by Bladder
Urologic Oncology Group (CUOG), and Canadian Urolog
2015

Canadian Urological Association Journal

10, 46

DOI: 10.5489/cuaj.3583

Citation Report

#	ARTICLE	IF	CITATIONS
1	Is there a measurable association of epidural use at cystectomy and postoperative outcomes? A population-based study. Canadian Urological Association Journal, 2016, 10, 321.	0.3	19
2	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	0.8	29
3	Association Between Anesthesiology Volumes and Early and Late Outcomes After Cystectomy for Bladder Cancer: A Population-Based Study. Anesthesia and Analgesia, 2017, 125, 147-155.	1.1	15
4	When the Gold Standard Proves to Be Fool's Gold"Blue-light Cystoscopy in a Case of High-risk Non-muscle-invasive Bladder Cancer. Urology, 2017, 110, 27-30.	0.5	2
5	Benchmarking our urological care: It's just the beginning. Canadian Urological Association Journal, 2017, 11, 223-4.	0.3	4
6	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 423-431.	0.8	16
7	A practical guide to bladder cancer pathology. Nature Reviews Urology, 2018, 15, 143-154.	1.9	36
8	Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2018, 199, 940-946.	0.2	34
9	Guideline of guidelines: asymptomatic microscopic haematuria. BJU International, 2018, 121, 176-183.	1.3	76
10	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Underused across the 49th parallel. Canadian Urological Association Journal, 2018, 13, 29-31.	0.3	9
11	Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy. Histopathology, 2018, 73, 732-740.	1.6	15
12	Imaging for the diagnosis and response assessment of renal tumours. World Journal of Urology, 2018, 36, 1927-1942.	1.2	59
13	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.3	9
14	Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World Journal of Surgical Oncology, 2018, 16, 6.	0.8	20
15	Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola,®) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2018, 4, 293-301.	0.2	10
16	Effect of centralization on complex surgical care: A population-based case study of radical cystectomy. Canadian Urological Association Journal, 2019, 14, 91-96.	0.3	4
17	The Prevalence of Bladder Cancer During Cystoscopy for Asymptomatic Microscopic Hematuria. Urology, 2019, 126, 34-38.	0.5	28
18	Quality Control Indicators for Transurethral Resection of Non-muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e784-e792.	0.9	40

#	ARTICLE	IF	CITATIONS
19	Quality and cost assessment of Canadian Urological Association microscopic hematuria guidelines in clinical practice: Turning urine into gold. Canadian Urological Association Journal, 2019, 13, 406-411.	0.3	6
20	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.3	3
21	Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File System. Frontiers in Oncology, 2019, 9, 1402.	1.3	3
22	Willingness to Participate in Home Screening for Urologic Cancers in the General Population: An Online Survey of Over 1400 Adults. Urology, 2020, 136, 35-40.	0.5	0
23	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology, 2020, 77, 583-598.	0.9	40
24	Crowdfunding in urology: Canadian perspective. Canadian Urological Association Journal, 2020, 15, E139-E143.	0.3	5
25	Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection. World Journal of Urology, 2020, 38, 2849-2856.	1.2	1
26	How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices. Urologia, 2020, 87, 142-148.	0.3	10
27	Microscopic hematuria. Cmaj, 2020, 192, E370-E370.	0.9	0
28	Prevalence of Urologic Disease Among Patients Investigated for Hematuria With CT Urography. Canadian Association of Radiologists Journal, 2021, 72, 228-233.	1.1	3
29	Diagnostic yield of repeat evaluation for asymptomatic microscopic hematuria after negative initial workup. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 300.e1-300.e6.	0.8	1
30	Accuracy of ultrasound vs computed tomography scan for upper urinary tract malignancies and development of a risk-based diagnostic algorithm for haematuria in a UK tertiary centre. International Urology and Nephrology, 2021, 53, 49-57.	0.6	2
31	Evaluation of Hematuria. , 2021, , 97-114.		0
32	Common Etiology and Analysis of Surgical Hematuria. Advances in Clinical Medicine, 2021, 11, 4068-4072.	0.0	0
33	The cost-effectiveness of schistosomiasis screening and treatment among recently resettled refugees to Canada: an economic evaluation. CMAJ Open, 2021, 9, E125-E133.	1.1	6
35	Cancer Prevalence and Risk Stratification in Adults Presenting With Hematuria: A Population-Based Cohort Study. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 308-319.	1.2	5
36	Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria. JAMA Network Open, 2021, 4, e218409.	2.8	16
37	Upper tract imaging modality to investigate haematuria: cancer detection rates and changing guidelines. African Journal of Urology, 2021, 27, .	0.1	1

#	ARTICLE	IF	CITATIONS
38	Management of Patients With Microhematuria. JAMA - Journal of the American Medical Association, 2021, 326, 563.	3.8	0
39	Urine Cytology in the Clinical Management of Bladder Cancer. , 2021, , 145-162.		1
40	Assist�ncia de enfermagem perioperat�ria aos pacientes com c�ncer de bexiga. Avances En Enfermer�a, 2016, 34, .	0.3	1
41	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.3	1
43	Haematuria: Evaluation and Management. , 2020, , 281-286.		0
44	Building the Canadian Bladder Cancer Research Network (CBCRN): Progress During a Pandemic. Canadian Urological Association Journal, 2022, 16, .	0.3	0
45	First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report. Anticancer Research, 2022, 42, 1339-1344.	0.5	1
53	Poster Session 11: EDI, COVID, Patient Relations. Canadian Urological Association Journal, 2022, 16, .	0.3	0
54	Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0